A Phase 3 interventional study of Product DNN.63.18.040 and Tramal® in Acute Pain, sponsored by Ache Laboratorios Farmaceuticos S.A.. Not yet recruiting. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment
This study evaluates the safety and efficacy of DNN.63.18.040 compared with Tramal® for the treatment of moderate to severe pain.
908 studies on the registry are indexed under Acute Pain; 154 are open to participants now.
This study's planned enrollment of 370 is above the median of 87 across 759 interventional studies indexed under Acute Pain.
Browse Acute Pain studies →Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Product DNN.63.18.040
Drug: Tramal®
One capsule four times daily for 3 days
One capsule four times daily for 3 days
Total Pain Relief Score (TOTPAR6)
Time-weighted sum of pain relief scores over the first 6 hours following the first dose. Pain relief is rated on a scale from 0 (no relief) to 4 (complete relief). TOTPAR6 ranges from 0 to 24, with higher scores indicating greater overall pain relief.
Time frame: 6 hours after first dose
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ache Laboratorios Farmaceuticos S.A. →